10-K/A: Quanterix Files Amendment No. 1 to Form 10-K/A to Include Part III Information

Quanterix Corporation files an amendment to its annual report to include information required by Part III of Form 10-K, which was initially omitted.

Summary

• Quanterix Corporation is filing Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024.
• The amendment includes information required by Part III of Form 10-K, which was omitted from the original filing on March 17, 2025, in reliance on General Instruction G(3) to Form 10-K.
• The company is filing this amendment because it does not expect to file the Proxy Statement within 120 days after the end of the fiscal year.
• This Amendment No. 1 amends and restates Items 10, 11, 12, 13, and 14 of Part III of the Original Form 10-K.
• The filing also includes certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 as Exhibit 31.3 and Exhibit 31.4.
• No other changes have been made to the Original Form 10-K.
• The aggregate market value of the voting and non-voting common equity held by non-affiliates as of June 30, 2024, was approximately $477 million.
• As of March 11, 2025, the company had 38,776,208 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, relating to the filing of an amendment. The sentiment is neutral, with a slight positive leaning due to the inclusion of information about executive compensation and corporate governance.

Positives

• Stockholders showed strong support (98%) for the executive compensation program at the 2024 annual meeting.

Negatives

• The company had to restate its audited Consolidated Financial Statements as of December 31, 2023 and 2022, and for each of the three years in the period ended December, 31 2023, unaudited Consolidated Financial Statements for the quarterly and year-to-date (as applicable) periods of 2022 and 2023 and unaudited Consolidated Financial Statements for the quarters ended March 31, 2024 and June 30, 2024 (collectively, the Restatement).

Risks

• The amendment does not reflect subsequent events occurring after the original filing date of the Original Form 10-K.
• The company's future performance is subject to various market and economic risks.

Future Outlook

The amendment does not provide any specific forward-looking statements or guidance.

Industry Context

The document provides information about Quanterix's corporate governance, executive compensation, and stock ownership, which are standard disclosures for publicly traded companies in the life sciences industry.

Comparison to Industry Standards

• The executive compensation disclosures align with industry standards, including base salary, annual cash incentives, and long-term equity incentives.
• The peer group used for compensation benchmarking includes companies like Adaptive Biotechnologies, Pacific Biosciences, and Twist Bioscience, which are relevant comparables in the life science tools and diagnostics sector.
• The stock ownership guidelines for non-employee directors and executive officers are a common practice to align their interests with those of stockholders.

Management Changes

Related Party Transactions

• The company has a license agreement with Tufts University, where director David R. Walt, Ph.D., previously served as a professor, and pays royalties on net sales of licensed products and services.
• The company also has a license agreement with Harvard University related to immunoassay technology developed by Dr. Walt at Harvard and Brigham and Women's Hospital.
• The company sells products and services to laboratories affiliated with Harvard and Brigham and Women's Hospital that are overseen by Dr. Walt.

Stakeholder Impact

• The amendment provides additional information to shareholders regarding corporate governance and executive compensation.
• The executive compensation programs are designed to align the interests of executives with those of stockholders.
• The company's policies and procedures for related party transactions are intended to ensure that such transactions are in the best interests of the company and its stockholders.

Next Steps

• The company will file the Proxy Statement at a later date.
• The company will continue to operate under its existing corporate governance policies and executive compensation programs.

Key Dates

Keywords

Form 10-K/A, amendment, executive compensation, directors, corporate governance, financial statements, Quanterix